Lyell Immunopharma Inc (LYEL) has a current stock price of $1.87. During the previous trading session, the stock witnessed a notable rise, reaching a high of $2.02 after opening at $2.02. The stock’s low for the day was $1.845, and it eventually closed at $2.05.
In terms of market performance, Lyell Immunopharma Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $4.63 on 11/18/22, while the lowest value was $1.32 on 10/09/23.
52-week price history of LYEL Stock
Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Lyell Immunopharma Inc’s current trading price is -59.61% away from its 52-week high, while its distance from the 52-week low is 41.67%. The stock’s price range for this period has remained between $1.32 and $4.63. The Healthcare sector company’s shares managed to surpass a trading volume of around 1.05 million for the day, which was noticeably higher compared to the shares’ average daily volume of 0.83 million over the last three months.
Financial Performance and Market Capitalization
Lyell Immunopharma Inc (LYEL) has experienced a quarterly decline of -16.52% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 471.00M and boasts a workforce of 274 employees.
Analysts’ Ratings For Lyell Immunopharma Inc
As of right now, 2 analysts are rating Lyell Immunopharma Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.17, with a change in price of -1.37. Similarly, Lyell Immunopharma Inc recorded 782,580 in trading volume during the last 100 days, posting a change of -42.28%.
LYEL Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LYEL stands at 0.09. Similarly, the long-term debt-to-equity ratio is also 0.08.
LYEL Stock Stochastic Average
As of today, the raw stochastic average of Lyell Immunopharma Inc over the past 50 days is 48.67%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 38.95%. Additionally, the Stochastic %K and %D values for the company were 46.32% and 34.21%, respectively, over the past 20 days.
LYEL Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The index has shown a price loss of -46.11% this year. Over the last six months, there has been a stronger performance of -25.79%. The price of LYEL fallen by 18.35% during the last 30 days period. For the last 5-days stocks have slided -14.61%.